Skip to Main Content

Sage Therapeutics is making a significant leadership change, hiring Barry Greene, the recently departed president of Alnylam Pharmaceuticals, as the biotech’s new chief executive officer.

Jeff Jonas, Sage’s CEO since 2013, will remain with the company as chief innovation officer. The official CEO handoff took place on Tuesday and was made public on Wednesday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!